These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22261685)

  • 1. CYP2C19 and clopidogrel response: more than validation in the real world.
    Shuldiner AR
    Clin Pharmacol Ther; 2012 Feb; 91(2):170-1. PubMed ID: 22261685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting clopidogrel response using DNA samples linked to an electronic health record.
    Delaney JT; Ramirez AH; Bowton E; Pulley JM; Basford MA; Schildcrout JS; Shi Y; Zink R; Oetjens M; Xu H; Cleator JH; Jahangir E; Ritchie MD; Masys DR; Roden DM; Crawford DC; Denny JC
    Clin Pharmacol Ther; 2012 Feb; 91(2):257-63. PubMed ID: 22190063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.
    Verschuren JJ; Boden H; Wessels JA; van der Hoeven BL; Trompet S; Heijmans BT; Putter H; Guchelaar HJ; Schalij MJ; Jukema JW
    Int J Cardiol; 2013 Sep; 167(6):2882-8. PubMed ID: 22940005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of Clopidogrel: An Unresolved Issue.
    Pereira NL; Geske JB; Mayr M; Shah SH; Rihal CS
    Circ Cardiovasc Genet; 2016 Apr; 9(2):185-8. PubMed ID: 27094200
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
    Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W
    Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics of antiplatelet drugs.
    Sabatine MS; Mega JL
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):343-7. PubMed ID: 25696877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
    Bhatt DL; Paré G; Eikelboom JW; Simonsen KL; Emison ES; Fox KA; Steg PG; Montalescot G; Bhakta N; Hacke W; Flather MD; Mak KH; Cacoub P; Creager MA; Berger PB; Steinhubl SR; Murugesan G; Mehta SR; Kottke-Marchant K; Lincoff AM; Topol EJ;
    Eur Heart J; 2012 Sep; 33(17):2143-50. PubMed ID: 22450429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina.
    Kim HS; Chang K; Koh YS; Park MW; Choi YS; Park CS; Oh M; Kim EY; Shon JH; Shin JG; Seung KB
    Circ Cardiovasc Genet; 2013 Oct; 6(5):514-21. PubMed ID: 24019397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current controversies in the pharmacogenomics of clopidogrel.
    Ensor CR; Cahoon WD
    Prog Cardiovasc Nurs; 2009 Sep; 24(3):105-9. PubMed ID: 19737169
    [No Abstract]   [Full Text] [Related]  

  • 11. Benefit of clopidogrel in recent myocardial infarction trials.
    Cardiovasc J S Afr; 2005; 16(3):182-3. PubMed ID: 16049599
    [No Abstract]   [Full Text] [Related]  

  • 12. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.
    Lansky AJ; Tsuchiya Y; Brener M; Mehran R; Cristea E; Pietras C; Grines CL; Cox DA; Garcia E; Tcheng JE; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Leon MB; Moses J; Stone GW
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):917-24. PubMed ID: 19016469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
    Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
    Zabalza M; Subirana I; Sala J; Lluis-Ganella C; Lucas G; Tomás M; Masiá R; Marrugat J; Brugada R; Elosua R
    Heart; 2012 Jan; 98(2):100-8. PubMed ID: 21693476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin.
    George J; Doney A; Palmer CN; Lang CC
    Cardiovasc Ther; 2010 Jun; 28(3):135-8. PubMed ID: 20557312
    [No Abstract]   [Full Text] [Related]  

  • 17. Variability of response to clopidogrel: possible mechanisms and clinical implications.
    Nguyen T; Frishman WH; Nawarskas J; Lerner RG
    Cardiol Rev; 2006; 14(3):136-42. PubMed ID: 16628022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study.
    So DY; Wells GA; McPherson R; Labinaz M; Le May MR; Glover C; Dick AJ; Froeschl M; Marquis JF; Gollob MH; Tran L; Bernick J; Hibbert B; Roberts JD
    Pharmacogenomics J; 2016 Feb; 16(1):71-8. PubMed ID: 25850030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.
    Leé S; Vargová K; Hizoh I; Horváth Z; Gulácsi-Bárdos P; Sztupinszki Z; Apró A; Kovács A; Préda I; Tóth-Zsámboki E; Kiss RG
    Thromb Res; 2014 Feb; 133(2):257-64. PubMed ID: 24359966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome p-450 polymorphisms and response to clopidogrel.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
    N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.